American Society of Hematology (ASH)

The American Society of Hematology (ASH) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal, Blood Advances.

Promising Results Seen with the Addition of Daratumumab to Standard of Care in Myeloma Patients Eligible for Transplant

ASH 2019 – Multiple Myeloma: Wrap-Up

In patients with newly diagnosed multiple myeloma who were fit for transplant, adding daratumumab to a commonly used treatment regimen led to impressive responses. Read More ›

The iR² Regimen in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

ASH 2019 – Wrap-up

Diffuse large B-cell lymphoma is an aggressive type of non-Hodgkin lymphoma that is particularly difficult to treat if the patient becomes refractory to or relapses after initial treatment. Chances of survival are especially poor for people who are not eligible for stem-cell transplant. Read More ›

Ibrutinib + Venetoclax for First-Line Treatment of CLL: Results from the MRD Cohort of the Phase 2 CAPTIVATE Study

ASH 2019 – Post Wrap-Up, ASH 2019 – CLL

In the minimal residual disease (MRD) cohort of the phase 2 CAPTIVATE study, first-line ibrutinib + venetoclax treatment resulted in high rates of undetectable MRD in both peripheral blood and bone marrow of patients with chronic lymphocytic leukemia (CLL). Read More ›

Lisocabtagene Maraleucel, a CD19-Directed CAR T-Cell Product, in High-Risk Patients with R/R CLL/SLL, Including Those Previously Treated with Ibrutinib

ASH 2019 – Wrap-up, ASH 2019 – Post Wrap-Up, ASH 2019 – CLL

Results from TRANSCEND CLL 004 showed chimeric antigen receptor (CAR) T-cell treatment with lisocabtagene maraleucel in heavily pretreated patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who had failed ibrutinib was manageable and produced durable undetectable minimal residual disease responses. Read More ›

Resistance to Acalabrutinib in Chronic Lymphocytic Leukemia Is Mediated Predominantly by BTK Mutations

ASH 2019 – Post Wrap-Up

For patients with chronic lymphocytic leukemia who are treated with acalabrutinib, disease progression is largely attributed to specific mutations in Bruton tyrosine kinase (BTK). Acalabrutinib resistance mechanisms are similar to those seen with ibrutinib. Read More ›

Possible New Treatment Option for Patients with Relapsed/Refractory Systemic Amyloid Light Chain Amyloidosis

ASH 2019 – Multiple Myeloma: Wrap-Up

Exciting research from the annual ASH conference showed that a new drug combination led to significant improvements in patients with systemic amyloid light chain amyloidosis. This could mean more treatment options for patients with a very limited choice of therapies. Read More ›

Venetoclax plus Rituximab in Relapsed/Refractory CLL: 4-Year Analysis

ASH 2019 – CLL

In a study that compared VenR (venetoclax plus rituximab) with standard chemoimmunotherapy in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), initial reports showed superior progression-free survival for VenR, as well as long-term benefits after patients stopped therapy. Read More ›

Triplet Therapy with Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

ASH 2019 – Post Wrap-Up

Use of a time-limited triplet combination of acalabrutinib, venetoclax, and obinutuzumab in patients with chronic lymphocytic leukemia offers high rates of undetectable minimal residual disease in bone marrow with acceptable tolerability. Read More ›

Daratumumab Added to Standard Therapy = Longer Survival in Newly Diagnosed Multiple Myeloma

ASH 2019 – Multiple Myeloma: Wrap-Up

When given daratumumab along with standard-of-care treatment, patients with newly diagnosed, transplant-ineligible multiple myeloma lived longer than those who received standard of care alone. Read More ›

Comparison of Therapies in Younger Patients with CLL

ASH 2019 – CLL

Results of the ECOG 1912 trial comparing chemoimmunotherapy with the oral BTK inhibitor ibrutinib plus rituximab in younger people with chronic lymphocytic leukemia (CLL). Read More ›

American Society of Hematology (ASH)

Page 17 of 44